Fremont, CA – According to filings with the U.S. Securities and Exchange Commission, Cytek BioSciences is raising $119,999,935.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Wenbin Jiang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cytek BioSciences

Cytek Biosciences is committed to providing powerful solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. We are on a mission to advance cancer and cell biology research using a powerful cell analysis technique called flow cytometry. We are satisfying long unmet needs in fields of research such as cancer biology, immunology and genomics, and helping to advance our collective understanding and diagnosis of cancer. Our products are used at many of the world’s most renown pharmaceutical and CRO firms and cancer research institutions. As a company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide.

To learn more about Cytek BioSciences, visit http://cytekbio.com/

Contact:
Wenbin Jiang, Chief Executive Officer
877-922-9835
https://www.linkedin.com/in/wenbin-jiang-4718541/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved